Eton Pharmaceuticals, Inc. (ETON)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$58.45-2.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ETON
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 5 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $58, ETON's earnings are too small for P/E to mean much; on sales it trades at 18× p/s (6.2× the 2.9× p/s peer median, and 1.2× even its own history). At a normal multiple the price implies ~59% near-term growth vs our ~74% forecast. That gap is an optionality premium a financial-multiple model can't price — our $37 fair value covers only the as-is business, low confidence. Analysts target $57–$70. Note: our $37 fair value sits below the entire analyst range ($57–$70). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $63.50 | — | — | Analyst | medium |
| Peer P/FCF | 12M | $6.34 | 14.1 | 0.45 | TTM | medium |
| Peer P/E | 12M | $11.57 | 16.1 | 0.72 | TTM | medium |
| Peer P/S | 12M | $9.36 | 2.9 | 3.22 | TTM | medium |
| triangulated | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$57.00 – $70.00 (median $63.50) · 6 analysts · as of 2026-08-14
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2024-Q3, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $10.94 |
| 16.1 |
| 0.68 |
| Triangulated |
| medium |
| Peer P/FCF | 3Y | $9.65 | 14.1 | 0.68 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $24.89 | 2.9 | 8.57 | Hist. CAGR(prov.) | medium |
| Peer P/FCF | 5Y | $12.76 | 14.1 | 0.90 | Hist. CAGR(prov.) | medium |
| Peer P/S | 5Y | $32.91 | 2.9 | 11.33 | Hist. CAGR(prov.) | medium |